Pfizer-BioNTech Can Supply 3 Billion Vaccine Doses This Year
(Bloomberg) -- BioNTech SE and Pfizer Inc. have the capacity to make as many as 3 billion doses of their Covid-19 vaccine this year, lifting their production target even as pressure mounts to waive their patents to boost global supply.
In 2022, the partners will further increase their capacity to more than 3 billion doses, BioNTech said in an e-mailed statement. Though the production goals aren't the same as firm orders, the increases more than double what the partners had said they'd be able to make less than six months ago.
As demand soars for messenger RNA Covid vaccines -- a new technology that has become a mainstay of the immunization effort -- Pfizer and BioNTech have repeatedly bumped up their production goals. The partners had said in March they could make 2.5 billion doses of their two-shot vaccine this year.
The latest boost comes after the U.S. government surprised the drug industry by announcing its support for a waiver of patent protections for Covid vaccines. The European Union and China signaled willingness to take part in the debate, though EU officials have cautioned that World Trade Organization negotiations will take months or years and that a waiver may not include mRNA technology.
Shares of BioNTech and other vaccine developers trimmed earlier declines after German Chancellor Angela Merkel pushed back against the effort to waive patent protections. The U.S. plan would create “severe complications” for the production of vaccines, according to a German government spokeswoman.
U.S. Vaccine Patent Surprise Roils Pharma as WTO Debate Heats Up
“Patents are not the limiting factor for the production or supply of our vaccine,” BioNTech said in the statement, arguing that a waiver wouldn't increase production and supply in the short and mid-term. Setting up and validating new vaccine manufacturing sites usually takes as long as a year, the company said.
One alternative to giving up patent rights would be a special license for manufacturers, Chief Executive Officer Ugur Sahin said at a briefing with journalists last week. Such production also wouldn't contribute much to supply until the end of next year, he said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.